ClinicalTrials.gg
RecruitingNCT05589337Updated Apr 29, 2026

Baduanjin Training for Depression and Anxiety Patients

An interventional study of Baduanjin and Health education in Depression Symptoms and Anxiety Symptoms, sponsored by Shanghai University of Traditional Chinese Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Shanghai University of Traditional Chinese Medicine · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jul 2021, registered Oct 2022).
  • Started Jul 2021; still recruiting 5 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

In recent years, the number of people with symptoms of depression or anxiety are on the rise. The aims of the prospective randomized study are: (1) to examine the effects of Baduanjin breathing training on reducing symptoms of depression or anxiety, and (2) to explore the correlates between improvements of depression or anxiety symptom and changes of lung functions.

Read the detailed description

Depression and anxiety, the two common mental health problems, are prevalent in the world. But there is a lack of sufficient no-drug intervention for relieving these two symptoms. The study focuses on mixed depressive and anxiety disorder, which symptoms are not sufficiently severe, numerous, or persistent to justify a diagnosis of depressive disorder or an anxiety disorder.

Baduanjin is a form of mind-body exercise with a profound philosophical foundation rooted in oriental culture. Previous studies have provided some evidences of beneficial effects on Baduanjin for depression and anxiety. Moreover, the effects and mechanisms of Baduanjin on patients with symptoms of depression and anxiety are yet to be further investigated.

This is a two-group prospective, randomized, assessor-blinded trial, planning to enroll 120 participants (60 for Baduanjin intervention group receiving health education plus a Baduanjin breathing training program, and 60 for health education control group only receiving health education).

The aims of the prospective randomized study are: (1) to examine the effects of Baduanjin breathing training on reducing symptoms of depression or anxiety, and (2) to explore the correlates between improvements of depression or anxiety symptom and changes of lung function.

02

Conditions studied

  • Depression Symptoms
  • Anxiety Symptoms

Keywords

  • Baduanjin
  • Depression
  • Anxiety
  • Randomized controlled trial
03

In context

Depression

8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.

This study's planned enrollment of 120 is above the median of 81 across 7,063 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Shanghai University of Traditional Chinese Medicine is the lead sponsor of 102 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject with depression or anxiety symptom diagnosed by ICD-10.
  • Depression 7≤HAMD-17≤29,anxiety 7≤HAMA-14≤29.
  • Subject has a clear mind and the ability to read, to talk and to communicate.
  • Subject agrees to participate in this study and sign to the .

Exclusion criteria

Exclusion Criteria:

  • Subject with bipolar disorder, psychotic disorder, organic mental disorder and cognitive disorder.
  • Subject with alcohol abuse, substance dependence and suicidal behavior in past-year.
  • Subject has severe somatic disease.
  • Subject is pregnant or lactating women.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Baduanjin intervention group

    Participants randomized to Baduanjin intervention group receive health education plus a Baduanjin training program. The Baduanjin training program was a 16-week, instructor-led group training program that offers breathing training as a core skill.

    Behavioral: Baduanjin · Behavioral: Health education

  • Active comparator
    Health education control group

    Participants randomized to the health education control group only receive health education and no additional training program.

    Behavioral: Health education

Interventions

  • BehavioralBaduanjin

    The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.

    Also known as: Eight-section Brocade

  • BehavioralHealth education

    Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.

06

What researchers measure

Primary outcomes

  1. 17-item Hamilton Depression Rating Scale

    The HAMD-17 is a clinician-rated assessment (structured interview) of patients' depressive symptoms. Questions focus on depressive symptoms during the past 7 days, and higher cumulative scores indicate more severe depression.

    Time frame: Change from Baseline HAMD-17 at 16 weeks

  2. 14-item Hamilton Anxiety Rating Scale

    The HAMA-14 is a clinician-rated assessment (structured interview) of patients' anxious symptoms. Questions focus on anxious symptoms during the past 7 days, and higher cumulative scores indicate more severe anxiety.

    Time frame: Change from Baseline HAMA-14 at 16 weeks

Secondary outcomes

  1. Depression, Anxiety and Stress Scale-21 item

    The DASS-21 is a self-rated assessment of patients' depressive, anxious and stress symptoms. Questions focus on depressive, anxious and stress symptoms during the past 7 days, and higher cumulative scores indicate more severe depression, anxiety and stress. Subscale scores are calculated as the sum of the responses to the seven items from each subscale multiplied by 2. The cutoffs for depression, anxiety, and stress are \>9, \>7, and \>14, respectively.

    Time frame: Change from Baseline DASS-21 at 8 weeks

  2. Depression, Anxiety and Stress Scale-21 item

    The DASS-21 is a self-rated assessment of patients' depressive, anxious and stress symptoms. Questions focus on depressive, anxious and stress symptoms during the past 7 days, and higher cumulative scores indicate more severe depression, anxiety and stress. Subscale scores are calculated as the sum of the responses to the seven items from each subscale multiplied by 2. The cutoffs for depression, anxiety, and stress are \>9, \>7, and \>14, respectively.

    Time frame: Change from 8 weeks DASS-21 at 16 weeks

  3. Vital capacity

    Vital capacity (VC) is tested by spirometry in the same machine (MINATO AS-507, Japan) and by the same clinicians following a standard protocol.

    Time frame: Change from Baseline VC at 16 weeks

  4. Forced vital capacity

    Forced vital capacity (FVC) is tested by spirometry in the same machine (MINATO AS-507, Japan) and by the same clinicians following a standard protocol.

    Time frame: Change from Baseline FVC at 16 weeks

  5. FVC percentage of predicted normal values

    FVC percentage of predicted normal values (FVC%) is tested by spirometry in the same machine (MINATO AS-507, Japan) and by the same clinicians following a standard protocol.

    Time frame: Change from Baseline FVC% at 16 weeks

  6. Forced expiratory volume in one second

    Forced expiratory volume in one second (FEV1) is tested by spirometry in the same machine (MINATO AS-507, Japan) and by the same clinicians following a standard protocol.

    Time frame: Change from Baseline FEV1 at 16 weeks

  7. The ratio of FEV1 to FVC

    The ratio of FEV1 to FVC (FEV1/FVC) is tested by spirometry in the same machine (MINATO AS-507, Japan) and by the same clinicians following a standard protocol.

    Time frame: Change from Baseline FEV1/FVC at 16 weeks

  8. Respiration rates

    The respiration rates are recorded by the same equipment (BioHarness, USA) and by the same clinicians following a standard protocol.

    Time frame: Change from Baseline respiration rates at 16 weeks

  9. Respiration depths

    The respiration depths are recorded by the same equipment (BioHarness, USA) and by the same clinicians following a standard protocol.

    Time frame: Change from Baseline respiration depths at 16 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2026, 65 months after the start.

Of 3,468 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 65 months is above that.

Counting every sponsor, half of 3,566 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2022
First posted
Oct 21, 2022
StartActual
Jul 1, 2021
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jul 30, 2027
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05589337
Responsible party
Lu Ying, MM (Research Associate, Shanghai University of Traditional Chinese Medicine) — Principal investigator
First posted
Oct 21, 2022
Start date
Jul 1, 2021
Primary completion
Dec 30, 2026 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Apr 29, 2026

Study contacts

Ying Lu, Master
Contact
luwing_happy@163.com
02154240423
Xiaoting Zhao
Contact
zxt7410@163.com
02154240423
Xiaoting Zhao
study chair · Shanghai Qigong Research Institute
Ying Lu
principal investigator · Shanghai Qigong Research Institute
Jie Li
study director · Shanghai University of Traditional Chinese Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion